119 related articles for article (PubMed ID: 9922045)
41. Establishment of the ELISA for murine soluble gp130, a signal transducer for the IL-6 family cytokine, and its detection in the ascitic fluids of tumor-bearing mice.
Matsuda T; Hirano T
Biochem Biophys Res Commun; 1994 Jul; 202(1):637-42. PubMed ID: 8037770
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
43. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
44. Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation.
Reinhold SW; Straub RH; Krüger B; Kaess B; Bergler T; Weingart C; Banas MC; Krämer BK; Banas B
Cytokine; 2012 Mar; 57(3):379-88. PubMed ID: 22209080
[TBL] [Abstract][Full Text] [Related]
45. High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption.
Dovio A; Perazzolo L; Saba L; Termine A; Capobianco M; Bertolotto A; Angeli A
Eur J Endocrinol; 2006 May; 154(5):745-51. PubMed ID: 16645023
[TBL] [Abstract][Full Text] [Related]
46. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
47. Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans.
Dekkers PE; Juffermans NP; ten Hove T; de Jonge E; van Deventer SJ; van der Poll T
J Infect Dis; 2000 Mar; 181(3):1055-61. PubMed ID: 10720531
[TBL] [Abstract][Full Text] [Related]
48. Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor.
Hashizume M; Yoshida H; Koike N; Suzuki M; Mihara M
Ann Rheum Dis; 2010 Apr; 69(4):741-6. PubMed ID: 19433409
[TBL] [Abstract][Full Text] [Related]
49. Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation.
Ishikawa H; Tsuyama N; Abroun S; Liu S; Li FJ; Otsuyama K; Zheng X; Kawano MM
Leuk Lymphoma; 2003 Sep; 44(9):1477-81. PubMed ID: 14565647
[TBL] [Abstract][Full Text] [Related]
50. [Interleukin-6 in pathogenesis of rheumatoid arthritis].
Mihara M; Nishimoto N
Nihon Rinsho; 2005 Jan; 63 Suppl 1():158-62. PubMed ID: 15799337
[No Abstract] [Full Text] [Related]
51. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.
Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J
Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270
[TBL] [Abstract][Full Text] [Related]
52. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M; Mihara M
Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
[TBL] [Abstract][Full Text] [Related]
53. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells.
Kang HS; Lee BS; Yang Y; Park CW; Ha HJ; Pyun KH; Choi I
Cell Immunol; 1996 Mar; 168(2):174-83. PubMed ID: 8640863
[TBL] [Abstract][Full Text] [Related]
54. Circulating interleukin 6 and soluble forms of its receptors in relation to resting energy expenditure in women with anorexia nervosa.
Karczewska-Kupczewska M; Adamska A; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
Clin Endocrinol (Oxf); 2013 Dec; 79(6):812-6. PubMed ID: 23199226
[TBL] [Abstract][Full Text] [Related]
55. Release of interleukin-6 and its soluble receptors by activated peripheral blood monocytes is elevated in hypocholesterolemic hemodialysis patients.
Tsirpanlis G; Chatzipanagiotou S; Boufidou F; Kordinas V; Alevyzaki F; Zoga M; Kyritsis I; Ioannou D; Fatourou A; Nicolaou C
Am J Nephrol; 2005; 25(5):484-90. PubMed ID: 16127269
[TBL] [Abstract][Full Text] [Related]
56. Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration.
Lehtimäki KA; Keränen T; Huhtala H; Hurme M; Ollikainen J; Honkaniemi J; Palmio J; Peltola J
J Neuroimmunol; 2004 Jul; 152(1-2):121-5. PubMed ID: 15223244
[TBL] [Abstract][Full Text] [Related]
57. [Cytokine binding proteins: a model of interleukin 6].
Brailly H; Montero-Julian FA
Arch Inst Pasteur Tunis; 1994; 71(3-4):535-48. PubMed ID: 8801856
[No Abstract] [Full Text] [Related]
58. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.
Pulsatelli L; Boiardi L; Pignotti E; Dolzani P; Silvestri T; Macchioni P; Cantini F; Salvarani C; Facchini A; Meliconi R
Arthritis Rheum; 2008 Aug; 59(8):1147-54. PubMed ID: 18668607
[TBL] [Abstract][Full Text] [Related]
59. Determination of IL6, IL1, and IL4 in the plasma of patients with multiple myeloma.
Kiss TL; Lipton JH; Bergsagel DE; Meharchand JM; Jamal N; Minden MD; Messner HA
Leuk Lymphoma; 1994 Jul; 14(3-4):335-40. PubMed ID: 7950924
[TBL] [Abstract][Full Text] [Related]
60. Myeloma biology and therapy. Present status and future developments.
Nishimoto N; Shima Y; Yoshizaki K; Kishimoto T
Hematol Oncol Clin North Am; 1997 Feb; 11(1):159-72. PubMed ID: 9081210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
